Qprotyn Inc
Wednesday, June 05, 2024
Platform for Therapeutics
Company Presentation Theater 4
At Qprotyn our mission is to advance HILOPRO® - our unique and patented viscosity-reducing technology for antibodies which enables them to be injectable subcutaneously, without the use of hyaluronidase.
HILOPRO® viscosity-reduction technology will facilitate a formulation at a concentration greater than 250mg/mL at injectable viscosities < 20cP. This would enable 500mg+ doses in a standard 2cc syringe with a 27 gauge needle. Our platform technology works with mAbs and other protein biologics, using two common and safe excipients in combination, and was patented in 2020.
.png)
Company Website:
http://www.qprotyn.com
Lead Product in Development:
HILOPRO® viscosity-reduction technology for high-concentration mAbs enabliing them for subcutaneous delivery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3 Products for High-Concentration (>250mg/mL with viscosity <20cP)
1. Innovator Monoclonal Antibodies
2. High Concentration SC Biosimilars
3. SC Immunoglobulins
Company HQ City
Cambridge
Company HQ State
Massachusetts
Company HQ Country
United States
CEO/Top Company Official
Lynn Hartung - President, Qprotyn Inc.
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())